Entera Bio Ltd (ENTX)

Entera Bio (ENTX) Stock Price & Analysis


ENTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.47 - $3.00
Previous Close$1.03
Average Volume (3M)239.80K
Market Cap
Enterprise Value$15.48M
Total Cash (Recent Filing)$14.32M
Total Debt (Recent Filing)$132.00K
Price to Earnings (P/E)-5.8
Mar 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding18,234,191
10 Day Avg. Volume56,720
30 Day Avg. Volume239,799
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)156.51
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue54.33
Enterprise Value/Gross Profit78.20
Enterprise Value/Ebitda-1.10
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.47 and its highest was $3.00 in the past 12 months.
    What is Entera Bio Ltd’s market cap?
    Currently, no data Available
    When is Entera Bio Ltd’s upcoming earnings report date?
    Entera Bio Ltd’s upcoming earnings report date is Mar 30, 2023 which is in 3 days.
      How were Entera Bio Ltd’s earnings last quarter?
      Entera Bio Ltd released its earnings results on Nov 10, 2022. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.025.
        Is Entera Bio Ltd overvalued?
        According to Wall Street analysts Entera Bio Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Entera Bio Ltd pay dividends?
          Entera Bio Ltd does not currently pay dividends.
          What is Entera Bio Ltd’s EPS estimate?
          Entera Bio Ltd’s EPS estimate is -$0.12.
            How many shares outstanding does Entera Bio Ltd have?
            Entera Bio Ltd has 28,809,921 shares outstanding.
              What happened to Entera Bio Ltd’s price movement after its last earnings report?
              Entera Bio Ltd reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went down -19.355%.
                Which hedge fund is a major shareholder of Entera Bio Ltd?
                Among the largest hedge funds holding Entera Bio Ltd’s share is RA Capital Management. It holds Entera Bio Ltd’s shares valued at 216K.


                  Entera Bio Stock Smart Score

                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Entera Bio Ltd

                  Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Chemomab Therapeutics
                  Neurosense Therapeutics Ltd.
                  Vascular Biogenics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis